Clearance or reduction of antibody titres (N) · adults with both late‐stage, symptomatic Chagas disease and CCC
Benznidazole may leads to higher clearance or reduction of antibody titres (N) (a) at 12 months (b)… compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement (N) · adults with both late‐stage, symptomatic Chagas disease and CCC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · adults with both late‐stage, symptomatic Chagas disease and CCC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (N) · adults with both late‐stage, symptomatic Chagas disease and CCC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clearance of parasitaemia demonstrated by negative xenodiagnosis, blood culture, and/or molecular assays (N) · adults with both late‐stage, symptomatic Chagas disease and CCC
It is very uncertain whether benznidazole changes clearance of parasitaemia demonstrated by negative xenodiagnosis,… compared with placebo (very low certainty).
1 finding from 1 review
Pathological demonstration of tissue parasites (N) · adults with both late‐stage, symptomatic Chagas disease and CCC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement (N) (a) Heart failure (b) Sustained ventricular tachycardia · adults with both late‐stage, symptomatic Chagas disease and CCC
Benznidazole showed no clear difference in clinical improvement (N) (a) Heart failure (b) Sustained ventricular… compared with placebo (low certainty).
1 finding from 1 review
Quality of life · adults with both late‐stage, symptomatic Chagas disease and CCC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (N) · adults with both late‐stage, symptomatic Chagas disease and CCC
Benznidazole probably leads to higher adverse events (N) compared with placebo (moderate certainty).
1 finding from 1 review
Clearance or reduction of antibody titres (N) · adults with both late‐stage, symptomatic Chagas disease and CCC
It is very uncertain whether nifurtimox changes clearance or reduction of antibody titres (N) compared with placebo (very low certainty).
1 finding from 1 review
Clearance of parasitaemia demonstrated by negative xenodiagnosis, blood culture, and/or molecular assays (N) · adults with both late‐stage, symptomatic Chagas disease and CCC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pathological demonstration of tissue parasites (N) · adults with both late‐stage, symptomatic Chagas disease and CCC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · people with multiple sclerosis
Antioxidant showed no clear difference in relapse(assessed as number of participants experiencing relapse) compared with placebo (low certainty).
1 finding from 1 review
Change in validated disability scale ( · people with multiple sclerosis
1 finding from 1 review
Global impression of deterioration (investigator defined global impression of deterioration) · people with multiple sclerosis
Antioxidant showed no clear difference in global impression of deterioration (investigator defined global… compared with placebo (low certainty).
1 finding from 1 review
Number of participants with gadolinium‐enhancing T1 lesions on MRI · people with multiple sclerosis
It is very uncertain whether antioxidant changes MRI activity(assessed as number of participants with… compared with placebo (very low certainty).
1 finding from 1 review
SAEs · people with multiple sclerosis
Antioxidant showed no clear difference in SAEs (assessed as number of participants experiencing a SAE) compared with placebo (low certainty).
1 finding from 1 review
Detumescence · men and boys with SCD and stuttering priapism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Effect on later sexual function · men and boys with SCD and stuttering priapism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other untoward side effects of treatment · men and boys with SCD and stuttering priapism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found